3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
17
Lymphoma, Follicular
15
Lymphoma
15
Multiple Myeloma
14
Lymphoma, Mantle-Cell
14
Leukemia, Myeloid, Acute
14
Leukemia, Lymphocytic, Chronic, B-Cell
14
Lymphoma, Non-Hodgkin
13
Leukemia
13
Hodgkin Disease
13
Congenital Abnormalities
13
Burkitt Lymphoma
13
Lymphoma, Large B-Cell, Diffuse
12
Lymphoma, B-Cell, Marginal Zone
12
Leukemia, Myeloid, Chronic-Phase
12
Lymphoma, Large-Cell, Immunoblastic
11
Leukemia, Myeloid, Accelerated Phase
11
Myeloproliferative Disorders
10
Myelodysplastic Syndromes
10
Recurrence
9
Primary Myelofibrosis
9
Lymphoma, T-Cell, Cutaneous
9
Dendritic Cell Sarcoma, Interdigitating
9
Blast Crisis
8
Sezary Syndrome
7
Mycosis Fungoides
7
Leukemia, Myelomonocytic, Chronic
7
Anemia, Refractory, with Excess of Blasts
7
Waldenstrom Macroglobulinemia
6
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
6
Interventions
fludarabine phosphate
1
fludarabine
1
Mesna
1
Cyclophosphamide
1
Busulfan
1
Alemtuzumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase NA
×
Thalassemia
×
fludarabine phosphate
×
Clear all
NCT00578292
2020-05-01
THALLO
Baylor College of Medicine
Phase NA
Terminated
10 enrolled
15 charts